Filing Flows › Nektar Therapeutics (NKTR) › Q2 2026 › vs Q2 2025
Nektar Therapeutics (NKTR) Q2 2026 vs Q2 2025 (year over year)
Nektar Therapeutics's revenue fell $1.0M (-9%) from $11.2M in Q2 2025 to $10.1M in Q2 2026.
Nektar Therapeutics, Q2 2026: revenue $10.1M (-9% year over year), operating margin -417.9%, net loss $40.6M, operating cash flow −$75.8M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.1M | $11.2M | −$1.0M | -9% |
| Other income, net | $1.7M | −$5.6M | $7.3M | — |
| Net loss | $40.6M | $41.6M | −$971K | -2% |
| Costs & expenses | $52.5M | $53.0M | −$482K | -0.9% |
| Operating costs | $52.5M | $47.4M | $5.1M | +11% |
| Income tax | $2K | −$188K | $190K | — |
| Research & development | $39.1M | $29.9M | $9.2M | +31% |
| General & admin | $12.8M | $17.1M | −$4.3M | -25% |
| Other operating costs | $578K | $447K | $131K | +29% |
| Operating cash sources | $79.3M | $49.4M | $29.9M | +60% |
| Depreciation & amortization | $156K | $214K | −$58K | -27% |
| Share-based compensation | $3.4M | $3.5M | −$121K | -3% |
| Cash used in operations | $75.8M | $45.7M | $30.0M | +66% |
| Net loss absorbed | $40.6M | $41.6M | −$971K | -2% |
| Working capital & other | $38.7M | $7.8M | $30.8M | +393% |
Questions
How much did Nektar Therapeutics's revenue grow year over year in Q2 2026?
Nektar Therapeutics's revenue fell $1.0M (-9%) from $11.2M in Q2 2025 to $10.1M in Q2 2026.